Neuronos is developing an oral small‑molecule drug that modulates nitric oxide signaling to normalize synaptic function linked to core autism spectrum disorder symptoms. The therapy is backed by animal model reversal data and human stem‑cell assays, and is moving into Phase 1 trials to assess safety and efficacy for clinicians and healthcare systems treating ASD.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autism spectrum disorder (ASD) currently lacks approved pharmacologic treatments that address its core behavioral symptoms, leaving patients and families without disease-modifying options.
Solution
Neuronos is developing a small‑molecule therapeutic that modulates nitric oxide signaling pathways implicated in ASD neurobiology. Preclinical studies in animal models have demonstrated reversal of ASD‑like phenotypes, and parallel experiments using human stem‑cell–derived neuronal cultures have shown comparable molecular and functional effects. The company is progressing this candidate into clinical trials to evaluate safety, tolerability, and efficacy in individuals with ASD, aiming to provide a disease‑targeted therapy for core symptoms.
Target Audience
Primary customers are clinicians and healthcare systems treating individuals with autism spectrum disorder, as well as patients and families seeking pharmacologic options for core symptom management.
Features
- Mechanistic focus on nitric oxide production to normalize synaptic function associated with ASD
- Preclinical validation showing phenotype reversal in multiple animal models
- Human stem‑cell assay data confirming translational relevance of the target pathway
- Clinical development plan encompassing Phase 1 safety assessment and subsequent efficacy trials
- Formulation designed for oral administration to facilitate outpatient treatment